Table 2.
Treatment | n* | Normal† | Primary constriction gaps (PCG) |
Total†‡ | FITotal§ | ||
---|---|---|---|---|---|---|---|
PCGI† | PCGII† | PCGIII† | |||||
Untransfected | 263 | 92.78 | 7.22 | 0.00 | 0.00 | 7.22 | 1.0 |
GAPD | 329 | 93.92 | 5.47 | 0.61 | 0.00 | 6.08 | 0.84× |
SMC1L1 | 238 | 79.41 | 11.34 | 6.30 | 2.94 | 20.59 | 2.85× |
CSPG6 | 313 | 77.04 | 11.64 | 8.18 | 3.14 | 22.96 | 3.18× |
STAG2 | 260 | 86.92 | 11.15 | 1.92 | 0.00 | 13.08 | 1.81× |
MRE11A | 294 | 80.95 | 14.97 | 2.72 | 1.36 | 19.05 | 2.64× |
*Number of mitotic spreads included in the analyses.
† Values represent percentages.
‡Total represents the sum of PCGI + PCGII + PCGIII.
§FITotal represents the relative fold increase of the total PCG for the indicated condition over that of the untransfected control population.